LD
IDXX icon

Lipe & Dalton’s Idexx Laboratories IDXX Stock Holding History

Lipe & Dalton’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Hold
790
– – 0.19% 62
2026
Q1 		$444K Hold
790
– – 0.23% 56
2025
Q4 		$534K Hold
790
– – 0.26% 58
2025
Q3 		$505K Buy
+790
New +$480K 0.25% 62

Other funds holding IDXX

MBI
Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.55B AUM 11.62% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $10.3B AUM 3.26% 1-Year Est. Return

Lipe & Dalton's IDXX Position: Q2 2026 in Review

Lipe & Dalton held its Idexx Laboratories (IDXX) position steady in Q2 2026 at 790 shares worth $416K. The position accounts for 0.19% of the portfolio, ranked #62.

Lipe & Dalton first reported a position in IDXX in Q3 2025 and has held it in 4 quarters since. The position peaked at $534K in Q4 2025. 509 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Lipe & Dalton held 790 shares of Idexx Laboratories worth $416K as of Q2 2026.
  • Lipe & Dalton left its Idexx Laboratories share count unchanged in Q2 2026.
  • Idexx Laboratories made up 0.19% of Lipe & Dalton's portfolio in Q2 2026, its #62 holding.
  • Lipe & Dalton first reported a position in Idexx Laboratories in Q3 2025 and has held it in 4 quarters since.
  • Lipe & Dalton's Idexx Laboratories position peaked at $534K in Q4 2025.
  • 509 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Lipe & Dalton's 13F filing for Q2 2026, filed 14 Jul 2026.